Anakinra for B-Cell Lymphoma

Memorial Sloan Kettering Cancer Center, New York, NY
B-Cell Lymphoma+2 More ConditionsAnakinra - Drug
All Sexes

Study Summary

This trial is testing if anakinra can prevent or reverse the severe side effects of CAR-T cell therapy.

Eligible Conditions
  • B-Cell Lymphoma
  • B-cell Acute Lymphoblastic Leukemia
  • Non-Hodgkin's Lymphoma

Treatment Effectiveness

Phase-Based Effectiveness

1 of 3
Phase 2

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 28 days from the start of treatment

Day 28
Arm 2 (COVID-19 Group) proportion of patients able to avoid death or mechanical ventilation
4 weeks
Arm 1 (CAR T Cell Group) Rate of Severe Neurotoxicities

Trial Safety

Phase-Based Safety

2 of 3
This is further along than 68% of similar trials

Side Effects for

Anakinra & Pentoxifylline & Zinc Sulfate
19%Acute Kidney Injury
9%Urinary tract infection
8%Upper GI hemorrhage
8%Clostridium difficile infection
6%Hepatic failure
6%C. difficile infection
4%Respiratory Failure
4%Multiple Organ Dysfunction Syndrome (MODS)
4%Esophageal varices hemorrhage
This histogram enumerates side effects from a completed 2018 Phase 2 & 3 trial (NCT01809132) in the Anakinra & Pentoxifylline & Zinc Sulfate ARM group. Side effects include: Acute Kidney Injury with 19%, Ascites with 11%, Nausea with 9%, Urinary tract infection with 9%, Upper GI hemorrhage with 8%.

Awards & Highlights

All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.
No Placebo Group
All patients enrolled in this trial will receive the new treatment.

Trial Design

2 Treatment Groups

Arm 1 (CART Cell Group)
1 of 2
Arm 2 (COVID-19 Group)
1 of 2

Experimental Treatment

62 Total Participants · 2 Treatment Groups

Primary Treatment: Anakinra · No Placebo Group · Phase 2

Arm 1 (CART Cell Group)
Experimental Group · 1 Intervention: Anakinra · Intervention Types: Drug
Arm 2 (COVID-19 Group)
Experimental Group · 1 Intervention: Anakinra · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 28 days from the start of treatment

Who is running the clinical trial?

Memorial Sloan Kettering Cancer CenterLead Sponsor
1,864 Previous Clinical Trials
591,570 Total Patients Enrolled
Jae Park, MDPrincipal InvestigatorMemorial Sloan Kettering Cancer Center
13 Previous Clinical Trials
405 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 0 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:

Frequently Asked Questions

Are there still spots available to participate in this experiment?

"This clinical trial, which was initially posted on October 30th 2019 is still seeking participants. Data hosted on shows the study has been recently revised as of August 22nd 2022." - Anonymous Online Contributor

Unverified Answer

In what medical situations is Anakinra typically employed?

"Anakinra is effective at treating systemic juvenile idiopathic arthritis (sjia) and some rarer inflammatory disorders, such as neonatal-onset multisystem inflammatory disease (nomid), receptors, interleukin-1, and steroids." - Anonymous Online Contributor

Unverified Answer

What other research has been conducted regarding the efficacy of Anakinra?

"In 2016, Anakinra was initially studied at Royal Glamorgan Hospital. Currently, there have been 68 completed trials and 33 experiments in progress; a significant number of these are located in the city of New York." - Anonymous Online Contributor

Unverified Answer

How hazardous is the use of Anakinra for individuals?

"Anakinra's safety has been partially verified in Phase 2 trials, so it was given a rating of 2. Unfortunately, there is yet to be sufficient evidence regarding its efficacy." - Anonymous Online Contributor

Unverified Answer

How many participants are being administered treatment in the ongoing research?

"Affirmative. records confirm that this trial, first posted on October 30th 2019 and recently updated on August 22nd 2022, is actively recruiting 62 subjects across 2 medical centres." - Anonymous Online Contributor

Unverified Answer
Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.